Scynexis (SCYX) Invested Capital (2013 - 2023)
Scynexis (SCYX) posted Invested Capital of $34.6 million for Q1 2023, up 371.47% on a QoQ basis from $7.3 million in Q3 2018.
Scynexis (SCYX) Invested Capital (2013 - 2023) Analysis & Trends
Scynexis' Invested Capital history runs 5 years deep, the most recent figure standing at $34.6 million for Q1 2023.
- Quarterly Invested Capital changed N/A year-over-year to $34.6 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $34.6 million (changed N/A YoY) and the FY2017 annual result came in at $4.3 million, changed N/A from the prior year.
- Invested Capital was $34.6 million for Q1 2023 at Scynexis, up from $7.3 million in the prior quarter.
- Across five years, Invested Capital topped out at $34.6 million in Q1 2023 and bottomed at $34.6 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 31.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 7.15 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.93 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 73.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 34.65 Mn |
| Sep 30, 2018 | 7.35 Mn |
| Jun 30, 2018 | 5.47 Mn |
| Mar 31, 2018 | 3.60 Mn |
| Dec 31, 2017 | 4.35 Mn |
| Sep 30, 2017 | 2.85 Mn |
| Jun 30, 2017 | 1.35 Mn |
| Mar 31, 2014 | 15.00 Mn |
| Dec 31, 2013 | 15.00 Mn |